Serial Number
98851818
Owner
Acrivon Therapeutics, Inc.Attorney
Sara M. BauerFiling Date
Nov 13, 2024
AP3 Trademark
Serial Number: 98851818
Trademark Classes
Owner Contact Info
480 Arsenal Way, Suite 100
Watertown, MA 02472
Entity Type: 03
Legal Representation
Correspondence Address
Sara M. Bauer Womble Bond Dickinson (US) LLP
470 Atlantic Ave; Suite 600
Independence Wharf
Boston, MA 02210
United States
Trademark Details
Filing Date
November 13, 2024
Registration Date
Not Registered
Goods & Services
Medical services; medical testing for diagnosis or treatment purposes; medical diagnostic testing, monitoring, and reporting services; providing medical information, consultancy and advisory services; individual medical counseling services provided to patients; providing a website featuring information in the field of precision medicine; providing medical information to medical professionals in the form of reports in the field of precision medicine; proteomics and biomarker discovery services, namely, medical diagnostic services
scientific research; medical research; proteomics and biomarker discovery services, namely, medical testing services and information in the field of disease classification; scientific research and development in the fields of pharmaceuticals, therapeutics, and drug formulation and delivery; scientific research and development in the fields of proteomics and biomarker discovery; consultancy services in the field of pharmaceutical research and development services; consultancy services in the fields of medical and scientific research concerning proteomics and biomarker discovery; pharmaceutical research services related to prediction of drug treatment efficacy; medical research services related to prediction of drug treatment efficacy; conducting scientific studies in the fields of proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, precision medicine clinical trials based on responder identification; proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, precision medicine clinical trials based on responder identification; providing information in the field of medical, scientific and pharmaceutical research about proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, precision medicine clinical trials based on responder indication services; scientific and technological research and consultation services, namely, in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, pharmacodynamic biomarkers, drug repurposing, patient responder identification, indication finding, and rational drug design; drug discovery services in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, patient responder identification, pharmacodynamic biomarkers, drug repurposing, and rational drug design through optimal pathway effects in intact cells; consultancy in the field of pharmaceutical research and development services in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, patient responder identification, pharmacodynamic biomarkers, drug repurposing, indication finding, and rational drug design through pathway-based SAR